Low dose, highly bioavailable curcumin extract supports joint comfort and mobility in new study, says OmniActive Health Technologies

In the study, 135 subjects with mild knee osteoarthritis received either 250 mg (50 mg curcuminoids) or 500 mg (100 mg curcuminoids) of Curcuwin Ultra+ per day for 84 days.

OmniActive Health Technologies (Morristown, NJ) has announced the results of a clinical study expected to be published later this year. In the study, 135 subjects with mild knee osteoarthritis received either 250 mg (50 mg curcuminoids) or 500 mg (100 mg curcuminoids) of Curcuwin Ultra+ per day for 84 days. Both doses resulted in improvements in overall joint health comfort and mobility as early as five days, and persisted throughout the study.

“The results of this robust study demonstrated that a low dose of just 250 mg (50 mg curcuminoids) of Curcuwin Ultra+ may serve as a unique nutritional solution for managing issues related to knee joint comfort and mobility including cartilage health,” said Deshanie Rai, PhD, FACN, vice president, global scientific and regulatory affairs at OmniActive, in a press release. The ingredient was shown in a study published earlier this year to be 144 times more bioavailable than standard curcumin at a dose of 250 mg.1

Reference

  1. Kothaplly S et al. “Superior bioavailability of a novel curcumin formulation in healthy humans under fasting conditions.” Advances in Therapy, vol. 39 (2022): 2128-2138